On this pageJump to a section
For two years the easiest pitch in cash-pay telehealth was "the same medication for far less." On November 6, 2025 the ground under that line moved.
The White House announced pricing agreements with Eli Lilly and Novo Nordisk for GLP-1 drugs. I am not here to argue the politics. I am here to tell clinic owners what was actually announced, what nobody knows yet, and how to build a business that does not depend on being the cheapest name on the page.
None of this is legal advice. It is an operator's read of public announcements. Talk to counsel before you change pricing, claims or the products you prescribe.
What was actually announced?
Start with the primary documents, because the headlines were messy.
From the White House fact sheet
The fact sheet, dated November 6, 2025, lists these terms:1
- Direct cash prices through TrumpRx: Ozempic and Wegovy, listed at $1,000 and $1,350 on the page, fall to $350. Zepbound and orforglipron (if approved) fall to an average of $346 from $1,086.
- Oral options if the FDA approves them: an initial dose of $150.
- Medicare and Medicaid: a $245 price for Ozempic, Wegovy, Mounjaro and Zepbound.
- Medicare beneficiaries: a $50 monthly copay, and Medicare coverage of Wegovy and Zepbound for patients with obesity and related conditions for the first time.
$245
The page gives no start dates or implementation timing for these terms.1
From Lilly
Lilly's own release the same day is more specific on its side. The lowest-dose Zepbound multi-dose pen is $299, with additional doses up to $449, which Lilly says is a $50 discount to current direct-to-patient prices. Orforglipron, if approved, starts at $149 for the lowest dose. Medicare beneficiaries would pay no more than $50 per month for Zepbound and for orforglipron, if it is approved, starting as early as April 1, 2026.2
Does not include pricing obligations in the commercial channel.
That one line matters. Lilly says the agreement does not set prices for commercially insured patients.2
From the press coverage
NPR reported that injectables sold through TrumpRx without insurance would average $350 a month, down from about $500, with the price expected to fall to $245 over 24 months. It reported that Medicare copays would start in April, and that the TrumpRx website was expected to launch in 2026 and redirect buyers to drugmakers' direct-to-consumer sites.3
What Novo's own channel looked like
Novo Nordisk's most recent price I can verify is from March 5, 2025, when NovoCare Pharmacy offered all Wegovy doses at $499 per month to cash-paying patients.4 I could not find a Novo release updating that price as of today, so I will not guess at one.
What is still unknown?
More than the headlines suggest. Before you change anything, note the gaps.
- Timing. The fact sheet gives no start dates. Lilly says Medicare copays could begin as early as April 1, 2026.12
- Availability. TrumpRx was described as launching in 2026.3 Until it exists, nobody can buy through it.
- Approval of oral drugs. The oral prices depend on FDA approval that had not happened when the deal was announced.12
- Channels for telehealth. None of the documents I read describe how a telehealth clinic participates or is paid.
- Novo's retail and direct pricing. The White House lists $350; Novo's own cash channel was $499 per its latest release I can verify.
What does this do to a clinic that competes on price?
It squeezes the line "cheaper than brand," a trend I flagged in When Manufacturers Sell Direct. If the manufacturers' own cash channels settle in the range of a few hundred dollars a month, a clinic whose pitch is "we are cheaper" has less room and a more skeptical patient.
Compounding is also a different regulatory story from the deal. The semaglutide shortage officially ended on February 21, 2025, and the compounding leeway that came with it ran out that spring.8 In September, the FDA and HHS announced a crackdown on misleading drug ads (my breakdown), and Holland & Knight reported that the agency sent warning letters to telehealth providers, flagging language such as "the same ingredient in Wegovy & Ozempic."56
Put those together (the Q4 2025 brief has the wider picture) and the stance is clear: do not use the new brand prices to claim anything about compounded products, and do not compare a compounded product to a brand in either direction.
The Novo and Hims lesson
The public split between Novo Nordisk and Hims & Hers in June is a reminder of how fast the story can turn. Novo ended its collaboration with the company, saying it sold "illegitimate, knockoff versions of Wegovy," according to CBS News.7 That is Novo's claim, not a ruling. The point for your clinic is that manufacturers, regulators and press are all watching the language.
What should a clinic sell if the drug is no longer the story?
The care. The drug is the commodity. The clinic is the product.
When patients can see a few hundred dollars a month as a market price, they start asking different questions: Who will actually look after me? (Month three is where clinics lose patients.) How quickly can I reach someone? What happens when I have side effects? What does the program cost beyond the medication?
Those are questions you can answer with facts about your service:
- Clinician access: how a patient reaches a licensed clinician and how long it takes.
- Follow-up cadence: the check-ins you actually perform.
- Clarity: a plain statement of what the patient pays, what is included and what is not.
- Sourcing transparency: where the medication comes from and who fills it.
- Support for the practical stuff: prior authorizations, refills, travel, what to do when a dose is missed.
If a patient fills a prescription through a manufacturer's direct channel, you are paid for care, not for the drug. Design the program so that is a feature, not a loss.
| Old story: price | New story: care |
|---|---|
| "The same drug for less" | "A clinician who knows your history and follows up" |
| Headline price per month | A clear, all-in program description |
| Compete with the lowest advertiser | Compete with the best experience |
| Margin depends on the drug | Margin depends on the service |
| Breaks when prices fall | Holds when prices fall |
Three kinds of clinic, three different moves
Not every cash-pay clinic is exposed in the same way. Find yourself in this list, and be honest about it.
The price-led clinic
Your whole pitch is a low monthly number. You are the most exposed, because the benchmark just moved and you have no second story. Your move is to build one fast: define the care, name the follow-up, and stop leading with price in your headlines. If price is your only reason to exist, a price cut ends you.
The access-led clinic
You win on speed and convenience: same-week visits, evening hours, quick messaging with a clinician. Falling prices hurt less because patients are paying for time. Your move is to document the experience, such as typical response times you can actually measure, and put it in plain words.
The condition-led clinic
You treat weight as part of a broader program, with labs, nutrition support and long-term monitoring. You are the least exposed, but you still need to price the program as a program, so patients understand what they pay you for beyond the medication.
Ask yourself which one you are, then write down what changes if the headline price of the drug falls by a third. If the honest answer is "everything," that is the project for this month.
How should you respond this week?
- Audit every price claim. Find each ad, page and email with a drug price or a comparison. Remove anything inaccurate, comparative or dependent on a program that has not launched.
- Rewrite the value story. List the five concrete things a patient gets from your clinic that a mail-order channel does not provide. Test them in plain words.
- Decide your product lanes. Which medications and channels will you support? Write down the rules for brand, for any compounded product and for patients who prefer a manufacturer channel.
- Rebuild the pricing page. Make it a program price that describes what the patient pays you, separate from any medication cost, and say how renewals work.
- Brief counsel. Show them the new copy and your claims ledger before the holiday promotions go live.
- Set a trigger list. Decide in advance what you will do when TrumpRx launches, when Novo updates its channel, and when any oral drug is approved.
What will probably happen next?
I do not predict policy, but I do know how markets behave. When a headline price falls, three things tend to follow: patients ask for it, competitors advertise it before it exists, and regulators watch the claims. You want to be the clinic that waits for facts, speaks plainly and is still there when the dust settles.
For the next few months, keep a short list of what you know for sure, what is announced but unconfirmed, and what is rumor. Update it weekly. Add a second list of questions patients are likely to ask, such as whether you will match a price or whether you can prescribe through a manufacturer channel, and write one calm answer to each. Share the confirmed section with your team so the front desk, the clinicians and the marketing person tell patients the same story.
When the price of the product falls, the only thing left to sell is who you are and how you treat people.
I have watched ad markets reset more than once since I started buying Meta traffic in 2014, usually faster than the people inside them expected. The operators who last stop competing on the thing that just got cheaper and start competing on the thing nobody can copy. For a clinic, that is trust, access and honesty about what you are doing. How I build those into a clinic's funnel is on my telehealth page.
Keep building.Ekai
Questions people ask
What did the November 2025 GLP-1 deal announce?
On November 6, 2025 the White House announced pricing agreements with Eli Lilly and Novo Nordisk. The fact sheet lists cash prices through TrumpRx of $350 for Ozempic and Wegovy and an average of $346 for Zepbound, a $245 Medicare and Medicaid price, and a $50 Medicare copay. Lilly separately set Zepbound self-pay at $299 to $449.
Do the new prices apply to compounded semaglutide or tirzepatide?
No. The agreements concern the manufacturers' approved products. The shortage ended on February 21, 2025, so compounding is back under the ordinary limits. Do not imply a compounded product matches a brand.
When does TrumpRx start?
The White House fact sheet gives no start dates, and NPR reported that the TrumpRx site was expected to launch in 2026. Do not advertise prices or availability that do not yet exist.
How should a cash-pay telehealth clinic respond to falling prices?
Stop competing on the price of the drug and compete on the quality of care: access to clinicians, follow-up, clarity and trust. Audit all price claims for accuracy and keep any promotions free of comparative drug claims. Educational, not legal advice.
Does the deal change what telehealth ads can say?
The deal itself does not change advertising rules. The FDA's September 2025 crackdown still applies, and FDA letters flagged language claiming compounded products were the same as brand drugs. Keep claims accurate and substantiated.
Sources
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
